General Information of Drug (ID: DM59TI2)

Drug Name
M9831 Drug Info
Synonyms
2-Methyl-1,3-benzothiazole-5-carboxylic acid; 24851-69-2; 2-Methylbenzo[d]thiazole-5-carboxylic acid; 2-Methyl-benzothiazole-5-carboxylic acid; 2-methyl-1,3-benzothiazole-5-carboxylic acid; 5-Benzothiazolecarboxylic acid, 2-methyl-; 2-methylbenzothiazole-5-carboxylic acid; SMR000015267; MLS000030206; AC1LDLFR; AC1Q2PD7; SCHEMBL1105986; cid_649953; CHEMBL1480093; CTK0J4554; KS-00000IVD; BDBM87603; DTXSID50349491; MolPort-002-499-021; TVUFPZOJUJGDDD-UHFFFAOYSA-N; HMS2396B08; ZINC873707; ZX-CM001754; ZX-AL001070; ANW-56675; AKOS000320290; FCH1781098; CS-W019372; MCULE-8154234969; FS
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
649953
CAS Number
CAS 24851-69-2
TTD Drug ID
DM59TI2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
M3814 DMK2L38 Locally advanced rectal cancer 2B92 Phase 1/2 [1]
AZD7648 DMD9Y5T Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
PP121 DMU8KTO Discovery agent N.A. Investigative [3]
LY-292223 DML36ZE Discovery agent N.A. Investigative [4]
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate DM3FH02 Discovery agent N.A. Investigative [5]
PIK-75 DM9BQTX Discovery agent N.A. Investigative [6]
KU-0060648 DMQWS6U Discovery agent N.A. Investigative [7]
Alpha-naphthoflavone DMELOIQ Discovery agent N.A. Investigative [8]
2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one DM79ZOV Discovery agent N.A. Investigative [8]
2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one DMAHZR9 Discovery agent N.A. Investigative [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA-dependent protein kinase catalytic (PRKDC) TTK3PY9 PRKDC_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun. 2019 Nov 7;10(1):5065.
3 Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
4 Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6083-7.
5 Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
6 A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47.
7 1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity. J Med Chem. 2013 Aug 22;56(16):6386-401.
8 Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.